首页> 外文期刊>Therapeutic Drug Monitoring >The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems
【24h】

The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems

机译:在接受抗逆转录病毒治疗并遇到药物相关问题的患者中,监测治疗药物的优势

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Therapeutic drug monitoring (TDM) of antiretroviral drugs (ARVs) is used to improve the efficacy and safety of ARVs, but there is little interest for the systematic or random TDM of ARVs in the medical management of patients with acquired immune deficiency syndrome. This study aimed to evaluate a different approach and test the potential advantages of TDM as part of medical treatments when clinical problems are identified in human immunodeficiency virus-infected patients. METHODS: The authors conducted a prospective, noncontrolled, cohort study on 544 human immunodeficiency virus-positive patients treated either with a protease inhibitor (PI), atazanavir/lopinavir, or with a nonnucleoside reverse transcriptase inhibitor (NNRTI), efavirenzevirapine. Patients who had virological failure, clinical signs of toxicity, or a risk of pharmacokinetic interactions were identified as having medication-related problems (MRPs), and they were scheduled for TDM of the PIs or NNRTIs. Cases with drug levels outside the range were subjected to intervention, and a second determination of plasma levels and viral load was scheduled to assess their response to the intervention. RESULTS: Of the 521 treatment courses analyzed, 173 (32.4%) presented at least 1 MRP during the study. The TDM yielded abnormal results in 52.5% of the 198 identified MRP cases (95% CI: 45%-59%). The patients treated with PIs had an increased risk for having drug plasma levels that fell outside the normal range compared to those treated with NNRTIs (relative risk =1.36, 95% CI: 1.04-1.79). The TDM-guided interventions contributed to the resolution of 52.1% of the cases that involved treatment courses with MRPs and abnormal drug plasma levels. CONCLUSIONS: MRPs, including therapeutic failure, were common in the patients who were included in the study. A high proportion of the treatment courses involving such MRPs also presented abnormal plasma drug levels. The TDM-guided interventions are advantageous under these situations because they allow the continuation of treatments that would otherwise be substituted by more complex and costly alternatives.
机译:背景:抗逆转录病毒药物(ARV)的治疗药物监测(TDM)用于提高ARV的疗效和安全性,但对于获得性免疫缺陷综合征患者的医疗管理,ARV的系统性或随机性TDM兴趣不大。这项研究旨在评估一种不同的方法,并在感染人类免疫缺陷病毒的患者中发现临床问题时测试TDM作为药物治疗的潜在优势。方法:作者对544例接受蛋白酶抑制剂(PI),阿扎那韦/洛匹那韦或非核苷逆转录酶抑制剂(NNRTI),依非韦伦/奈韦拉平治疗的544名人类免疫缺陷病毒阳性患者进行了一项前瞻性,非对照队列研究。病毒学衰竭,毒性的临床体征或药代动力学相互作用的风险的患者被鉴定为患有药物相关问题(MRP),并计划将其用于PI或NNRTI的TDM。对药物水平超出范围的病例进行干预,并计划再次确定血浆水平和病毒载量,以评估其对干预的反应。结果:在分析的521个治疗方案中,有173个(32.4%)在研究期间至少表现出1个MRP。在198例MRP确诊病例中,TDM产生异常结果的占52.5%(95%CI:45%-59%)。与使用NNRTIs治疗的患者相比,接受PIs治疗的患者血浆血浆水平超出正常范围的风险更高(相对风险= 1.36,95%CI:1.04-1.79)。由TDM指导的干预措施有助于解决52.1%的涉及MRP和药物血浆水平异常的治疗过程的病例。结论:包括治疗失败在内的MRPs在本研究中很常见。涉及此类MRP的大部分治疗过程还显示血浆药物水平异常。在这些情况下,由TDM指导的干预措施是有利的,因为它们允许继续治疗,否则这些治疗方法将被更为复杂和昂贵的替代方法所替代。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号